## David J Bond

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6565318/publications.pdf

Version: 2024-02-01

80 papers 6,106 citations

32 h-index 72 g-index

82 all docs 82 docs citations

82 times ranked 6078 citing authors

#	Article	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments ( <scp>CANMAT</scp> ) and International Society for Bipolar Disorders ( <scp>ISBD</scp> ) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
3	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
4	Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2008, 111, 135-144.	4.1	442
5	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology, 2009, 12, 447.	2.1	343
6	A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine, 2015, 45, 693-704.	4.5	311
7	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a metaâ€analysis. Bipolar Disorders, 2012, 14, 478-487.	1.9	184
8	3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 263-71.	2.4	140
9	A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophrenia Research, 2001, 52, 37-46.	2.0	135
10	Neurocognitive Functioning in Patients With Bipolar I Disorder Recently Recovered From a First Manic Episode. Journal of Clinical Psychiatry, 2010, 71, 1234-1242.	2.2	134
11	Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder. Journal of Clinical Psychiatry, 2008, 69, 1589-1601.	2.2	113
12	Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis. Journal of Affective Disorders, 2010, 124, 228-234.	4.1	106
13	A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability. Journal of Psychiatric Research, 2015, 62, 23-30.	3.1	93
14	Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project. Canadian Journal of Psychiatry, 2009, 54, 105-112.	1.9	85
15	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Annals of Clinical Psychiatry, 2012, 24, 23-37.	0.6	74
16	Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychological Medicine, 2011, 41, 971-982.	4.5	73
17	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disorders, 2020, 22, 440-460.	1.9	66
18	Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in firstâ€episode mania and association with clinical outcome. Bipolar Disorders, 2016, 18, 511-519.	1.9	64

#	Article	IF	CITATIONS
19	The Association of Elevated Body Mass Index with Reduced Brain Volumes in First-Episode Mania. Biological Psychiatry, 2011, 70, 381-387.	1.3	62
20	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. Journal of Affective Disorders, 2016, 191, 216-221.	4.1	62
21	Mania secondary to focal brain lesions: implications for understanding the functional neuroanatomy of bipolar disorder. Bipolar Disorders, 2016, 18, 205-220.	1.9	61
22	Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. Comprehensive Psychiatry, 2009, 50, 1-8.	3.1	55
23	Which Depressive Symptoms and Medication Side Effects Are Perceived by Patients as Interfering Most with Occupational Functioning?. Depression Research and Treatment, 2012, 2012, 1-6.	1.3	50
24	Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis. British Journal of Psychiatry, 2017, 210, 403-407.	2.8	50
25	12â€month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disorders, 2014, 16, 159-171.	1.9	49
26	Body Mass Index–Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients. Biological Psychiatry, 2014, 76, 138-145.	1.3	48
27	Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. Journal of Affective Disorders, 2013, 150, 408-414.	4.1	46
28	Cognitive Change in the Year After a First Manic Episode. Journal of Clinical Psychiatry, 2014, 75, e587-e593.	2.2	45
29	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Translational Psychiatry, 2018, 8, 188.	4.8	44
30	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Molecular Psychiatry, 2016, 21, 1050-1056.	7.9	42
31	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology, 2016, 65, 76-83.	2.7	37
32	Systematic review of neurocognition and occupational functioning in major depressive disorder. Neuropsychiatry, 2013, 3, 97-105.	0.4	36
33	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. JAMA Psychiatry, 2019, 76, 1285.	11.0	36
34	Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. International Clinical Psychopharmacology, 2008, 23, 88-94.	1.7	32
35	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
36	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12â€month data from the Systematic Treatment Optimization Program for Early Mania (STOPâ€EM). Bipolar Disorders, 2010, 12, 616-626.	1.9	31

#	Article	IF	Citations
37	The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM) Journal of Affective Disorders, 2013, 148, 424-430.	4.1	31
38	Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. Journal of Affective Disorders, 2019, 245, 679-685.	4.1	31
39	Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Affective Disorders, 2010, 124, 108-117.	4.1	29
40	Clinical features of bipolar spectrum with binge eating behaviour. Journal of Affective Disorders, 2016, 201, 95-98.	4.1	29
41	Oxcarbazepine in the Treatment of Bipolar Disorder: A Review. Canadian Journal of Psychiatry, 2006, 51, 540-545.	1.9	28
42	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
43	The relationship between clinical outcomes and quality of life in firstâ€episode mania: a longitudinal analysis. Bipolar Disorders, 2013, 15, 188-198.	1.9	25
44	Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective <scp>MRI</scp> study. Bipolar Disorders, 2019, 21, 50-60.	1.9	23
45	Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. International Clinical Psychopharmacology, 2012, 27, 91-99.	1.7	22
46	Relationship between frontostriatal morphology and executive function deficits in bipolar I disorder following a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania ( <scp>STOP</scp> â€≼scp>EM). Bipolar Disorders, 2013, 15, 657-668.	1.9	22
47	Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12â€month study. Acta Psychiatrica Scandinavica, 2017, 135, 239-249.	4.5	20
48	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Affective Disorders, 2017, 208, 291-297.	4.1	20
49	Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling. Translational Psychiatry, 2019, 9, 149.	4.8	19
50	Neurocognitive Functioning in Overweight and Obese Patients with Bipolar Disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Canadian Journal of Psychiatry, 2014, 59, 639-648.	1.9	18
51	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
52	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. Journal of Clinical Psychiatry, 2017, 78, 441-448.	2,2	18
53	Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Psychiatric Research, 2014, 48, 65-72.	3.1	17
54	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. British Journal of Psychiatry, 2016, 208, 146-152.	2.8	16

#	Article	IF	CITATIONS
55	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.9	14
56	Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. Translational Psychiatry, 2017, 7, e1071-e1071.	4.8	13
57	Causal pathways to social and occupational functioning in the first episode of schizophrenia: uncovering unmet treatment needs. Psychological Medicine, 2023, 53, 2041-2049.	4.5	11
58	Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features. International Clinical Psychopharmacology, 2011, 26, 146-150.	1.7	10
59	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. International Journal of Neuropsychopharmacology, 2018, 21, 108-113.	2.1	10
60	Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. Australian and New Zealand Journal of Psychiatry, 2017, 51, 65-74.	2.3	9
61	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.7	9
62	<sup>13</sup> C Magnetic Resonance Spectroscopy and Glutamate Metabolism in Mood Disorders: Current Challenges, Potential Opportunities. American Journal of Psychiatry, 2014, 171, 1240-1242.	7.2	7
63	Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder. Journal of Affective Disorders, 2020, 270, 30-35.	4.1	5
64	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. JMIR Research Protocols, 2021, 10, e31439.	1.0	5
65	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. Journal of Affective Disorders, 2022, 310, 150-155.	4.1	5
66	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. Journal of Psychiatric Research, 2017, 95, 208-212.	3.1	4
67	Assessment of Proteomic Measures Across Serious Psychiatric Illness. Clinical Schizophrenia and Related Psychoses, 2017, 11, 103-112.	1.4	3
68	Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. Frontiers in Psychiatry, 2022, 13, 884217.	2.6	3
69	Forum – Melancholia. Current Opinion in Psychiatry, 2007, 20, 202-203.	6.3	1
70	Bipolar II disorder in context: a review of epidemiology, disability and economic burden., 0,, 46-55.		1
71	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.9	1
72	Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. Psychological Medicine, 2021, , 1-9.	4.5	1

#	Article	IF	CITATIONS
73	Comparison of Demographic and Clinical Features of Bipolar Disorder in Persons of African and European Ancestry. Journal of Racial and Ethnic Health Disparities, 2023, 10, 367-372.	3.2	1
74	Forum – Melancholia. Current Opinion in Psychiatry, 2007, 20, 203-205.	6.3	0
75	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. Psiquiatria Biologica, 2009, 16, 60-69.	0.1	0
76	Current status of mood stabilisers in the management of Bipolar II disorder., 0,, 114-125.		0
77	Comprehensive Pharmacologic Management of Bipolar Depression. Current Treatment Options in Psychiatry, 2014, 1, 263-277.	1.9	0
78	Mood Stabilisers in the Treatment of Bipolar II Disorder. , 2019, , 129-142.		0
79	Investigating the complex relationship between bipolarity and obesity: "Not because it is easy, but because it is hard― Bipolar Disorders, 2019, 21, 106-107.	1.9	0
80	A Multidisciplinary First-Episode Psychosis Program. Psychiatric Annals, 2015, 45, 561-568.	0.1	0